Sobi publishes its Report for the Fourth Quarter and Full

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 19, 2015 at 2:15 AM

Sobi publishes its Report for the Fourth Quarter and Full Year 2014

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the fourth quarter and full year 2014. Revenues for the year totalled SEK 2,607 M (2,177), an increase of 20 per cent. Revenues in the fourth quarter were 15 per cent higher compared to the previous year. All parts of the business contributed to the result with Orfadin® and the Partner Products portfolio delivering strong performance. Business Highlights Q4 2014 * Received positive opinion by the CHMP regarding Xiapex for the treatment of Peyronie's disease * Exercised opt-in right for Elocta(TM) * Marketing Authorisation Application for Elocta filed and validated for review by EMA * Orfadin approved in Japan Financial Highlights Q4 2014 (Q4 2013) * Total revenues were SEK 705.3 M (610.8) * Product revenues were SEK 575.3 M (448.0) * Gross margin was 60 per cent (59) * EBITA was SEK 38.2 M (65.2) * EBITA excluding write-downs (Multiferon) was SEK 63.4 M (65.2) Financial Highlights FY 2014 (FY 2013) * Total revenues were SEK 2,607.0 M (2,176.7) * Product revenues were SEK 1,988.8 M (1,557.7) * Gross margin was 59 per cent (59) * EBITA was SEK -43.4 M (211.0) * EBITA excluding write-downs (Kiobrina/Multiferon) was SEK 306.7 M (211.0) * Ended the year with a cash position of SEK 519.1 M (445.1)([1]) "2014 was a pivotal year for Sobi marked by excellent commercial performance across the portfolio. Total revenues were SEK 2,607 million, an increase of 20 per cent over the prior year and above our estimates. Cash flow increased year over year and gross margin was stable," said Geoffrey McDonough, CEO and President. "Looking at our development portfolio, the positive results of the Kids A-LONG study paved the way for the European filing of Elocta in October 2014, making EU approval possible before the end of 2015. As a result we formally exercised our opt-in right to take over final development and commercialisation in our territories. During 2014 we have been focused on building a world class haemophilia organisation to support launch and commercialisation and this will be expanded in 2015." Financial Summary Q4 Q4 Full year Full year Amounts in SEK M 2014 2013 Change 2014 2013 Change Total revenues 705.3 610.8 15% 2,607.0 2,176.7 20% ----------------------------------------------------------------- Gross profit 426.6 358.3 19% 1,547.8 1,284.0 21% ----------------------------------------------------------------- Gross margin 60% 59% 59% 59% ----------------------------------------------------------------- EBITA(2) 38.2 65.2 -41% -43.4 211.0 <-100% ----------------------------------------------------------------- EBITA excluding 63.4 65.2 -3% 306.7 211.0 45% write-downs ----------------------------------------------------------------- EBIT (Operating -32.7 -4.9 <-100% -325.0 -66.6 <-100% profit/loss) ----------------------------------------------------------------- Profit/loss for -17.4 -13.4 -30% -267.8 -93.0 <-100% the period (2) 2014 FY includes write-downs relating to Kiobrina of SEK 324.9 M and Multiferon of SEK 25.2 M. Multiferon is also included in the quarter. Outlook 2015 For 2015, Sobi expects total revenues for the full year to be in the range of SEK 2,800 to 3,000 M, and gross margin to be in the range of 58-60 percent. Operating costs are projected to increase as the company continues to prepare for the planned launch of Elocta. Sobi expects EBITA to be in line with the adjusted 2014 level. The outlook for 2015 is based on current exchange rates, and excludes revenue from the European launch of Elocta. - - - Sobi's report for the fourth quarter and full year 2014 can be found on http://www.sobi.com/Investors--Media/Reports/. About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. For more information please contact Media relations Investor relations Oskar Bosson Jörgen Winroth Head of Communications VP, Head of Investor Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506 +46 8 697 2135 oskar.bosson@sobi.com jorgen.winroth@sobi.com The information was released for public distribution on 19 February 2015 at 08:00 CET. -------------------------------------------------------------------------------- [1] The decisions to add XTEN to the company's collaboration with Biogen Idec and to exercise the opt-in right for Elocta impacted the cash flow with SEK -124.7 M [HUG#1895617]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Preplanning Funerals: Choices for Clarity and Comfort

Making Clear Plans for the Inevitable Man, if life is certain about one thing, it’s the endgame. And nobody wants to pass the buck on sorting out the details when they’re six feet under. Enter funeral preplanning – a chance to write the script for your own final episode and keep your family out of the weeds when the time comes. Jake Leonetti over at Stone Chapel...

LIME Faces Investigation Amid Earnings Shortfall

Financial Miss Spurs Investigation When you've been in this racket as long as I have, you learn that missing consensus earnings even by a few cents can stir up a financial hornet's nest. That's precisely where Neutron Holdings Inc., better known as Lime, finds itself. With their third-quarter earnings slipping two cents below expectation, at $0.63 against a $0.66 to $0.68...

Lakefront Living: Steuben County's Twin Tales

Here’s how it is: choosing a lakefront home in Steuben County, Indiana, ain't just about picking a place with a killer view. It’s like buying a lifestyle package and you’d better know what you’re getting. An article by Tony Isa, the go-to real estate guru in these parts, puts the spotlight on Lake James and Clear Lake—but what matters is how each might wrangle...

What Business Owners Need to Know About Glass Replacement

Understanding the Nuts and Bolts of Storefront Glass Replacement Picture your storefront beaten and battered, glass cracks spidering over once-pristine panes. Cue Matt Sears of Bentonville Glass Inc. ready to patch things up without turning your business into a disaster zone. The homegrown hero makes his debut in HelloNation's latest chat, offering the kind of advice you...

West Virginia Water's $850K Upgrade: A Local Boost

$850,000 For Aging Pipes: A Long-Needed Move Picture a dusty road in West Virginia—Old Route 38. Now, imagine it bustling with work crews hustling to give the town’s water infrastructure a much-needed facelift. West Virginia American Water is laying down $850,000 to replace 3,500 feet of worn-out pipe with durable PVC, aiming to curb service outages and ensure...

China's Health-Driven Poverty Approach Offers Global Lessons

China's Health Strategy in Poverty Reduction Here's a story that's got global implications tucked into its every corner: China, a country that's been trying to mesh healthcare with poverty reduction, has caught the eye of international observers. This insight was splashed across the latest Lancet Commission report, showcased at Tsinghua University on October 29. It seems...

Unlikely Collaborators Grants $7.2M to Boost Nonprofits

Massive Boost for Nonprofits Across the United States It's not every day you see millions thrown into nonprofit work without some fanfare, right? Unlikely Collaborators just poured a hefty $7.2 million into the coffers of 52 nonprofit outfits scattered across the nation. This spread isn't just about slapping cash on projects—it's about putting Elizabeth R. Koch's...

Crocs™ Gains C2C Circularity Gold for Classic Clogs

Turning Plastic into Gold Well, folks, Crocs isn't just about comfort anymore. They're wrapping their iconic Classic Clog in a shiny new accolade: Cradle to Cradle Certified® Circularity Gold Version 5.0. Imagine that—an award for making something meant to last, designed to be repurposed. They're not just slapping new paint on the same old clogs either. This...

Tokenized Stock Trading Takes Flight With SEC Nod

Tokenization Breaks New Ground You hear this, folks? We’ve got a whole new chapter kicking off in the stock market here in the U.S., and it's all about tokenized equities. Yeah, that’s right—tokenized stocks are finally getting a nod from the big guns at the SEC. Tradecraft just hit a milestone by facilitating the first-ever tokenized stock transaction under the...

Menarini & Ryvu's Phase II Results Offer Hope in B-NHL

New Glimmers of Hope in B-cell NHL Battle Battling aggressive B-cell non-Hodgkin lymphoma (B-NHL) isn't for the faint of heart, especially when standard treatments have been run through like an old pair of boots. Enter dapolsertib, the fresh-faced newcomer in Menarini Group and Ryvu Therapeutics' arsenal, showing encouraging signals in early Phase II results. These...